Physician profile
Emily Catherine Keller
NPI 1790928497
$90,772.21
in general payments reported to CMS, 2019-2025
33 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,781 · 2020: $8,511 · 2021: $16K · 2022: $2,828 · 2023: $6,913 · 2024: $32K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $7,380 · Consulting Fee: $4,725 · Travel and Lodging: $3,195 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,488.00 |
| Food and Beverage | $7,380.29 |
| Consulting Fee | $4,725.00 |
| Travel and Lodging | $3,194.89 |
| Education | $268.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $58,376.85 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $17,140.68 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $5,362.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,389.82 | 2019-2025 | |
| Lilly USA, LLC | $1,173.29 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $997.73 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Abbvie INC. | $936.36 | 2019-2025 | |
| Janssen Biotech, INC. | $907.43 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $643.90 | 2019-2025 | Adbry, Spevigo, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $553.01 | 2019-2024 | Cabtreo, Jublia |
| Genzyme Corporation | $390.55 | 2019-2025 | |
| Dermavant Sciences, INC. | $362.76 | 2023-2024 | Vtama |
| Incyte Corporation | $327.46 | 2021-2025 | Opzelura |
| Amgen INC. | $319.45 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $316.86 | 2020-2025 | Dupixent, Libtayo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $279.97 | 2019-2024 | |
| Revance Therapeutics, INC. | $177.67 | 2025 | Daxxify |
| Vyne Pharmaceuticals INC. | $176.57 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $151.15 | 2019-2023 | |
| Almirall LLC | $150.47 | 2019-2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.30 | 2022-2025 | Spevigo |
| Organon LLC | $99.28 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $92.23 | 2019 | |
| Journey Medical Corporation | $66.20 | 2019-2023 | |
| Prugen, INC. Pharmaceuticals | $64.05 | 2019 | |
| Dermira, INC. | $34.56 | 2020-2021 | |
| Merz North America, INC. | $33.28 | 2020-2023 | Xeomin |
| Epi Health, LLC | $29.50 | 2020-2022 | |
| Springworks Therapeutics, INC. | $27.35 | 2025 | Gomekli |
| Lnhc, INC | $18.71 | 2025 | Zelsuvmi |
| Encore Dermatology INC. | $14.80 | 2020 | |
| Arcutis Biotherapeutics, INC. | $12.93 | 2023 | |
| Glenmark Therapeutics INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.